Back to Research Library
Research Areas 9 min read

Fat Metabolism Research Overview

Current state of research on AOD-9604, Semaglutide, and lipolysis peptides.

Introduction

Fat metabolism — spanning lipolysis, lipogenesis, fatty acid oxidation, and adipose tissue biology — represents one of the most clinically consequential areas in contemporary metabolic research. Peptides have emerged as particularly precise research instruments, capable of targeting specific receptors and signalling pathways with a selectivity that small molecules often cannot match.

Adipose Tissue as an Active Endocrine Organ

Modern research has established that adipose tissue functions as far more than a passive energy depot. It operates as an active endocrine organ, releasing numerous signalling molecules (adipokines) and expressing an array of receptors responsive to circulating hormones and nutritional signals.

Key pathways of interest in fat metabolism research include:

  • •Beta-adrenergic signalling: Catecholamines bind beta-3 receptors on adipocytes, triggering cAMP-mediated lipase activation and fat release
  • •Insulin/IGF-1 axis: Promotes triglyceride storage and actively suppresses lipolysis via PI3K/Akt signalling
  • •GH/IGF-1 axis: Growth hormone is a potent driver of lipolysis
  • •GLP-1 axis: Incretin pathway with roles in appetite suppression, gastric emptying, and adipose biology

AOD-9604

AOD-9604 (Anti-Obesity Drug 9604) is a modified peptide fragment of human Growth Hormone (hGH), corresponding to amino acid positions 176–191 in the GH sequence, with an additional tyrosine residue added at the N-terminus.

Origins

AOD-9604 emerged from research at Monash University, Australia, with the specific objective of separating GH's lipolytic activity from its other metabolic actions — particularly the IGF-1-driven anabolic effects and the associated insulin resistance.

Mechanism of Action

In contrast to intact GH, AOD-9604:

  • •Does not activate the classical growth hormone receptor (GHR)
  • •Does not raise circulating IGF-1 concentrations
  • •Does not alter blood glucose or insulin levels in the majority of published studies
  • •Is believed to stimulate fat release through an alternative receptor pathway, potentially involving beta-3 adrenergic signalling

Research Findings

  • •Obese rodent models demonstrated significant adipose tissue reductions with AOD-9604 treatment
  • •Observed effects appeared specific to fat tissue rather than lean mass
  • •Phase II clinical studies in human subjects showed an acceptable safety profile with some evidence of efficacy
  • •The compound holds GRAS (Generally Recognised as Safe) status from the US FDA — an uncommon designation for a research peptide

Current Standing

AOD-9604 advanced further through the clinical development pipeline than most peptides in its category, though it did not reach pharmaceutical approval. It continues to feature in metabolic research investigations.

GLP-1 Receptor Agonists in Research

GLP-1 (Glucagon-Like Peptide-1) is a gut-derived incretin hormone released from intestinal L-cells following nutrient intake. Over the past decade it has become arguably the most clinically transformative area within peptide science.

Semaglutide

A long-acting GLP-1 receptor agonist with structural modifications extending its biological half-life to approximately 7 days:

  • •Reduces food intake via central (hypothalamic) GLP-1 receptor engagement
  • •Decelerates gastric emptying
  • •Stimulates insulin secretion in a glucose-dependent manner
  • •Large clinical trial programmes (STEP) demonstrated approximately 15% mean body weight reduction

Research Applications Beyond Weight

Semaglutide and related GLP-1 agonists are actively being investigated for:

  • •Mechanisms underpinning central appetite suppression
  • •Cardioprotective and renoprotective effects observed independently of weight changes
  • •Neurological interactions — GLP-1 receptors are present in the brain, raising interest in neurodegenerative research
  • •Addiction biology — emerging data pointing to effects on the brain's reward processing systems

Tirzepatide (GIP/GLP-1 Dual Agonist)

A newer compound combining agonism at both GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide) receptors:

  • •Superior weight reduction in clinical trials (~21% in SURMOUNT-1 programme)
  • •Enhanced metabolic outcomes relative to single-receptor GLP-1 agonism
  • •Research interest in parsing the distinct contributions of GIP versus GLP-1 receptor activation

CJC-1295 and the GH–Lipolysis Relationship

As discussed in the Growth Hormone Secretagogue article, GHRH analogues such as CJC-1295 drive GH secretion. GH itself is a potent pro-lipolytic signal:

  • •Directly activates hormone-sensitive lipase (HSL) within adipocytes
  • •Stimulates fatty acid mobilisation and oxidation
  • •Exerts anti-lipogenic effects on developing fat cells

Research into GHRH analogues in metabolic contexts investigates this GH-mediated pathway as a route to body composition modification.

MOTS-c

MOTS-c is a mitochondrially-encoded peptide with significant metabolic influence:

  • •Activates AMPK (AMP-activated protein kinase), a central cellular energy sensor
  • •Enhances glucose uptake and utilisation in peripheral tissues
  • •Reduces fat accumulation in metabolic disease models
  • •Circulating MOTS-c levels decline with age, suggesting relevance to age-related metabolic deterioration

Adiponectin-Derived Peptides

Adiponectin is an anti-inflammatory, insulin-sensitising hormone secreted by adipose tissue. Research into adiponectin-derived peptides (including ADP355 and related compounds) investigates:

  • •The mechanisms of adiponectin receptor engagement
  • •Metabolic consequences of receptor agonism
  • •Potential applications in metabolic syndrome research models

Research Methodology

Studies of fat metabolism peptides typically use the following methodological approaches:

  • •Indirect calorimetry: Measures oxygen consumption and CO₂ output to calculate respiratory quotient and fat oxidation rate
  • •DEXA scanning (in animal models): Provides precise body composition data
  • •Adipose tissue biopsy analysis: Examines gene expression, lipolytic enzyme activity, and tissue morphology
  • •Stable isotope tracers: Tracks labelled fatty acids to quantify metabolic flux

Gut Microbiome Interactions

Emerging evidence highlights important connections between gut microbial populations, GLP-1 secretion, and adipose biology:

  • •Specific bacterial species can promote GLP-1 release from intestinal L-cells
  • •Bacterially-produced short-chain fatty acids exert effects on adipose tissue signalling
  • •Some metabolic effects of peptide interventions may be partly mediated through the gut microbiome

This article is provided for research and educational purposes only.

Research Use Only: All products are sold strictly for in-vitro laboratory research purposes. Not for human or veterinary consumption. Not approved by the MHRA for any therapeutic use. Not intended to diagnose, treat, cure, or prevent any disease. Purchaser must be 18+ and a qualified researcher.

King Pharma

King Pharma is a UK-based supplier of independently verified, laboratory-grade peptide research compounds. All products are supplied for qualified scientific research use only.

⚠️ None of our products are intended for human use. No medicinal claims are made or implied.

© 2026 King Pharma Ltd. All rights reserved. Registered in England & Wales.

Secure payments:
VISAMCAMEXMaestro